Medical-Commercial Alignment in Rare Disease Launches Fails Long Before Launch Day, Experts Warn
核心洞察
Senior Medical Affairs leaders at the MAPS EMEA 2026 roundtable concluded that Medical-Commercial alignment failures in rare disease launches originate well before launch, often during clinical development.
The most common breakdown occurs between Medical Affairs and Clinical Development, where trials designed solely around FDA endpoints leave gaps for European HTA and payer requirements.
Leadership culture, not process frameworks, drives genuine alignment; patient-centred C-suite decision-making is essential for cross-functional cohesion.
By the time friction between Medical and Commercial teams becomes visible during a rare disease launch, the root causes have already been embedded for years—often stretching back to clinical development decisions made before phase 3 enrolment begins. This was the central finding from a roundtable of nine senior global Medical Affairs leaders convened by Spectrum Science (搜索) at the Medical Affairs Professional Society (MAPS) EMEA Annual Meeting in May 2026.
The discussion, which included representatives from organisations ranging from small biotechs to large global pharmaceutical companies, tackled a direct question: how can Medical and Commercial teams stay aligned amid real-world launch constraints? The answer pointed to an uncomfortable reality. "Alignment does not fail at launch; it breaks much earlier," participants concluded. "Rare disease launches do not fail because teams are misaligned on activity. They fail because we are not focused on whether those activities are cohesively building toward a change in clinical practice."
Culture over process: alignment as a leadership output
The strongest consensus in the room was that launch excellence frameworks alone do not create genuine Medical-Commercial alignment. Rather, alignment must originate from within leadership culture. When teams are measured on activity but judged on outcomes, alignment becomes performative rather than genuine.
"When senior leaders, including the C-suite, are visibly patient-centred in how they allocate resources and make decisions, not just in how launch frameworks are worded or KPIs tracked, alignment follows," the roundtable participants noted. "When leadership is fragmented or ambiguous, no cross-functional process can compensate."
In rare diseases (搜索), the stakes are uniquely high. Patient communities are small, expert clinicians are scarce, and every interaction carries reputational weight. A single inconsistency between Medical and Commercial narratives can undo months of relationship-building, and in an era of instant information access, such inconsistencies surface quickly.
Clinical development: the upstream alignment failure
Perhaps the most striking finding was that the most common alignment failure was not between Medical and Commercial, but between Medical Affairs and Clinical Development. Trials designed around US FDA endpoints can leave significant gaps for European health technology assessment (HTA) bodies, leaving Medical Affairs to launch with data that does not answer payer questions.
The fix, while organisationally difficult, is clear: Medical Affairs must co-author clinical development plans rather than conducting post hoc reviews. This is not simply about access to data but about shaping the clinical narrative early enough to change clinical practice. Critically, the window to influence endpoint selection closes well before phase 3 enrolment begins.
This upstream challenge is echoed in broader industry analysis. Successful launches increasingly begin in early clinical development, with the target product profile (TPP) defining what success looks like by aligning clinical ambition with the needs of prescribers, patients, and payers. Best-practice organisations bring commercial, medical affairs, and market access input into this phase early—often from phase 2—ensuring that evidence generation supports both regulatory approval and reimbursement.
The broken insight loop
Roundtable participants agreed that insights from Medical Science Liaisons (MSLs), Medical Information, congresses, advisory boards, and patients are strategically critical. Yet systems for capturing, synthesising, and acting on these insights are often inadequate.
The causes are structural: time pressure, inconsistent customer relationship management (CRM) adoption, and differing definitions of what constitutes a genuine insight. Most damaging is what participants termed the "black box" problem—valuable face-to-face interactions disappear because they are never formally recorded. As AI synthesis tools become standard, their output will only be as good as the data captured.
In genuinely unmapped rare diseases (搜索), this challenge is compounded. Pre-defining categories too early risks filtering out the most important signals. The recommendation was that insight capture should be phased: open and broad before launch, then structured once the landscape becomes clearer.
Three domains of ownership ambiguity
Participants identified three recurring sources of friction: data dissemination, encompassing publications, congress strategy, and medical education; external stakeholder engagement, including experts, patient advocacy, and payers; and safety communications.
In rare diseases (搜索), these domains are acutely sensitive. The same expert clinician may serve simultaneously as an external medical expert, a commercial speaker, and an advisory board member, encountering both Medical and Commercial teams around the same time. Ownership must be defined before launch pressure arrives, because as pressure builds, ambiguity drives poor decision-making, slows execution, and ultimately compresses the window to improve patient outcomes.
The cost of looking inward
A recurring theme was that teams are often drowning in internal reporting, consultant-led launch frameworks, and cross-functional meeting cycles precisely when external understanding matters most. In that environment, momentum stalls—not because teams lack activity, but because they lack a clear link between effort and impact.
Medical Affairs' unique value in rare disease—scientific relationships with expert physicians, proximity to patient communities, and real-time field insights—depends on time spent externally. AI can expedite some processes, but it cannot replace trusted interaction. Internal reporting that drives no actionable decision represents an opportunity cost that is rarely quantified and rarely discussed.
Strategic imperatives for Medical Affairs leaders
The roundtable distilled three concrete actions for Medical Affairs leaders. First, secure formal input into evidence generation, endpoint selection, and real-world evidence plans before the window closes. Second, build the pre-launch architecture for insight capture, synthesis, and cross-functional decision-making, with clear definitions and decision rights. Third, stop allowing internal reporting, legacy launch frameworks, and proxy KPIs to consume time that should be used to build external understanding and scientific credibility.
The reframe that resonated most clearly was this: stop treating Medical-Commercial alignment as a coordination problem and start treating it as shared ownership of commercialisation. Alignment is not proven by whether teams are coordinated—it is proven by whether their combined efforts are sustained through to changing clinical practice to improve patient outcomes.
As the broader launch environment grows more complex, with the EU Joint Clinical Assessment increasing the need for HTA-ready evidence earlier in development and pricing pressures requiring more deliberate launch sequencing decisions, the imperative for early cross-functional collaboration has never been stronger. Launch excellence is now defined by the quality of decisions made across the entire lifecycle, and those decisions cannot be made in isolation.